Quotes 5-day view Delayed Euronext Paris
10/19/2020
10/20/2020
10/21/2020
10/22/2020
10/23/2020
Date
85.72(c)
84.62(c)
83.36(c)
82.74(c)
82.94(c)
Last
997 632
1 473 313
1 868 864
1 888 397
1 224 867
Volume
-0.36% -1.28% -1.49% -0.74% +0.24% Change
Sales 2020
36 584 M 43 393 M 43 393 M
Net income 2020
11 429 M 13 556 M 13 556 M
Net Debt 2020
7 902 M 9 373 M 9 373 M
P/E ratio 2020
9,17x
Yield 2020
3,85%
Sales 2021
38 170 M 45 273 M 45 273 M
Net income 2021
5 754 M 6 824 M 6 824 M
Net Debt 2021
5 110 M 6 061 M 6 061 M
P/E ratio 2021
17,6x
Yield 2021
4,04%
Capitalization
104 B 123 B 124 B
EV / Sales 2020
3,06x
EV / Sales 2021
2,86x
Nbr of Employees
100 409
Free-Float
89,0%
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows:
- pharmaceutical products (84.1%): for the treatment of cardio-vascular diseases, thrombosis, central nervous system disorders (insomnia, multiple sclerosis, epilepsy), cancers, allergies, etc. Moreover, Sanofi-Aventis markets OTC products and generic drugs;
- human vaccines (15.9%): pediatric vaccines,...
Notations Surperformance© of Sanofi
Trading Rating : Investor Rating :
News in other languages on SANOFI
Analyst Recommendations on SANOFI
SANOFI - 09/04
One could take advantage of the market's hesitation
BUY
M&A spikes in record third quarter as boards go on pandemic deal spree
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends SANOFI
Short Term Mid-Term Long Term Trends Bearish Bearish Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
26
Average target price
105,53 €
Last Close Price
82,94 €
Spread / Highest target
48,1%
Spread / Average Target
27,2%
Spread / Lowest Target
2,48%
Please enable JavaScript in your browser's settings to use dynamic charts.
1st jan. Capitalization (M$)
SANOFI -7.45% 123 347
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
